GABARAPL2: A Protein Targeted for Neurological Disorders (G11345)

Target Name: GABARAPL2

NCBI ID: G11345

GABARAPL2

GABARAPL2: A Protein Targeted for Neurological Disorders

GABARAPL2 (FLC3A) is a protein that is expressed in various tissues throughout the body, including the brain. It is a key regulator of synaptic plasticity, which is the ability of the brain to change and adapt over time. GABARAPL2 has been shown to play a role in the development and progression of a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. As a result, GABARAPL2 has become a focus of interest for researchers as a potential drug target or biomarker.

GABARAPL2 was first identified in 2006 as a gene that was highly expressed in the brain. It is located on the X chromosome and has been shown to play a role in the development and maintenance of synaptic plasticity. Synaptic plasticity is the ability of the brain to change and adapt over time, and it is a key factor in the development of intelligence and learning.

GABARAPL2 is a protein that is expressed in various tissues throughout the body, including the brain. It is a key regulator of synaptic plasticity, which is the ability of the brain to change and adapt over time.

Studies have shown that GABARAPL2 is involved in the development and progression of a number of neurological and psychiatric disorders. For example, researchers have found that individuals with the genetic variation in GABARAPL2 are at increased risk of developing Alzheimer's disease. Additionally, GABARAPL2 has been shown to be involved in the development of depression and anxiety.

As a result, GABARAPL2 has become a focus of interest for researchers as a potential drug target or biomarker. Researchers are studying GABARAPL2 to see if they can develop drugs that target this protein and treat a variety of neurological and psychiatric disorders.

One way that researchers are studying GABARAPL2 is to use techniques such as RNA interference and live cell imaging to see how the protein is expressed and how it interacts with other proteins in the brain. This research is helping scientists to better understand the role of GABARAPL2 in the development and progression of neurological and psychiatric disorders.

Another way that researchers are studying GABARAPL2 is to develop drugs that target the protein. This is an active area of research, and scientists are working to develop drugs that can treat a variety of neurological and psychiatric disorders by targeting GABARAPL2.

GABARAPL2 has also been shown to be involved in the regulation of neural networks, which are the fundamental units of the brain. This is important because neural networks are responsible for a wide range of brain functions, including perception, movement, and language. By targeting GABARAPL2, researchers hope to be able to develop drugs that can improve neural network function and treat a variety of neurological and psychiatric disorders.

In conclusion, GABARAPL2 is a protein that is expressed in various tissues throughout the body, including the brain. It is a key regulator of synaptic plasticity, and has been shown to play a role in the development and progression of a number of neurological and psychiatric disorders. As a result, GABARAPL2 has become a focus of interest for researchers as a potential drug target or biomarker. Researchers are studying GABARAPL2 to see if they can develop drugs that target this protein and treat a variety of neurological and psychiatric disorders.

Protein Name: GABA Type A Receptor Associated Protein Like 2

Functions: Ubiquitin-like modifier involved in intra-Golgi traffic (By similarity). Modulates intra-Golgi transport through coupling between NSF activity and SNAREs activation (By similarity). It first stimulates the ATPase activity of NSF which in turn stimulates the association with GOSR1 (By similarity). Involved in autophagy (PubMed:20418806, PubMed:23209295). Plays a role in mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production (PubMed:20418806, PubMed:23209295). Whereas LC3s are involved in elongation of the phagophore membrane, the GABARAP/GATE-16 subfamily is essential for a later stage in autophagosome maturation (PubMed:20418806, PubMed:23209295)

The "GABARAPL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GABARAPL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets